Clozapine-induced hepatitis confirmed by rechallenge
Kanani, Muhammad-Kazim Nandhra, Harpal
Kanani, Muhammad-Kazim
Nandhra, Harpal
Citations
Altmetric:
Affiliation
Coventry and Warwickshire Partnership NHS Trust
Other Contributors
Publication date
2019-08-13
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Clozapine is an atypical antipsychotic that holds a unique role in the management of treatment-resistant schizophrenia. Well known side-effects include agranulocytosis and myocarditis but associated hepatic disorders are less familiar and listed under ‘rare or very rare’ by the British National Formulary.1 However, a transient elevation of transaminases has been estimated to affect up to 50% of patients treated with clozapine.2 This article describes a patient with minimally elevated LFTs who subsequently developed symptomatic hepatitis following the initiation of clozapine therapy.
Citation
Kanani MK, Nandhra H. Clozapine-induced hepatitis confirmed by rechallenge. Progress in Neurology and Psychiatry 2019; 23(3): 18–20.
Type
Article